Alan Ashworth, Ph.D., F.R.

Alan Ashworth is President of the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, a role he began in January 2015.  He was previously Chief Executive of the Institute of Cancer Research (ICR) in London, United Kingdom.  Dr. Ashworth's research focuses on understanding breast cancer genetics and applying what he learns to change the way patients are treated. He was a key part of the team that identified the BRCA2 breast cancer susceptibility gene, which is linked to an increased risk of some types of cancer.  Dr. Ashworth found a way to kill off BRCA1- and 2-related tumor cells by treating them with PARP inhibitors, which amplifies the damage caused by the broken DNA repair machinery in those cells.  This exemplifies the genetic principle of synthetic lethality in cancer therapy.

Dr. Ashworth is an elected member of EMBO and the Academy of Medical Sciences and a Fellow of the Royal Society. He has been the recipient of a number of scientific prizes and awards including The European Society of Medical Oncology Lifetime Achievement Award, the David T. Workman Memorial Award of the Samuel Waxman Cancer Research Foundation and the Meyenburg Foundation's Cancer Research Award and was the inaugural winner of the 2013 Basser Global Prize. He is the recipient of the 2015 Genetics Society Medal.

Peter Houghton, Ph.D.

Dr. Peter Houghton received his bachelor's in Pharmacy from the University of Bradford, and his Ph.D. in Biochemistry/Pharmacology from the University of London, Institute of Cancer Research, Surrey, England. In 2014, Dr. Houghton became Director of the Greehey Children's Cancer Research Institute (GCCRI), and holder of the Greehey Distinguished Chair for the Children's Cancer Research Institute.  Previously, he was Director of the Center for Childhood Cancer holding the Elizabeth M. & Richard M. Ross Endowed Chair in Pediatric Research.  Prior to Nationwide Children's Hospital, Dr. Houghton held various positions at St. Jude Children's Research Hospital, Memphis, TN.  Dr. Houghton's research has been focused on developing relevant models of rare childhood cancer that have been useful in identifying novel drugs (e.g. camptothecins) and understanding the biology of these tumors.  Dr. Houghton serves as a member of the Steering Committee, Phase I Consortium, and the Developmental Therapeutics Committee, of the Children's Oncology Group.

Martin List, Ph.D.

Martin List, Ph.D. Martin received a Pharmacy degree in 1984 from Julius Maximilian, University in Wurzburg and a Ph. D. in Pharmaceutical Technology in 1987 from the University of Basel, Switzerland. He worked at Sandoz from 1984 to 1996 where he was involved with various programs in dosage form and analytical development. In 1997, he joined Roche, Basel, where among other positions he was Department head, dosage form development and Department head, global Product Supply Chain Leaders. In 2012, Martin became engaged in supply chain project management.

David Parkes, Ph.D.

Dr. David Parkes has more than 28 years of experience in scientific discovery and drug development in the fields of diabetes, obesity, NAFLD/NASH and cardiovascular disease.  He has held senior level roles in both Discovery Research and Medical Affairs at Amylin Pharmaceuticals Inc., following his extensive training in globally-recognized medical research institutes. David most recently served as Senior Director of Discovery Research at Amylin Pharmaceuticals, where he led the preclinical development of exenatide, culminating in the approval and global commercialization of two “standard of care” drugs (Byetta and Bydureon) for the treatment of diabetes. He played a pivotal role in global scientific education for exenatide, pramlintide and metreleptin, three first in class drugs for the treatment of metabolic diseases. David has played a lead scientific role on alliance teams with partners including Eli Lilly, Takeda and Psychogenics, and is currently a senior scientific consultant for companies including Astra Zeneca, Profil, Novartis, Spitfire and Renova. David received his PhD in Pharmacology from the University of Melbourne, Australia, and has published over 90 scientific articles in high-impact journals.

Roland Thieme, Ph.D.

Roland Thieme, Ph.D. Roland Thieme recently retired from heading small molecule development of Roche Basel. He was a member of the small molecule development leadership team located in Basel, Switzerland and of several technical governance committees.

Roland received his Master of Science in 1982 and his PhD in 1986 from the Albert-Ludwigs-University in Freiburg, Germany. He joined Roche in 1986 and in 1992 built a group for analytical development. From 1999 until 2001 he was technical team leader and responsible for CMC activities of early phase development and supply chain management activities of several projects. In 2001 he became head of the clinical Supply Center Basel with responsibility for scale-up and GMP manufacturing of the small molecule API portfolio. From 2002 to 2016 Roland was responsible for the global API development at Roche Basel, Tech Center Boulder/Colorado and the chemical development group in Florence/South Carolina. He served as Head of Process Research and Technical Development incl. Analytical Development & Clinical supply.

ProLynx has strong research and clinical alliances with Key Opinion Leaders in DDR

Francois-Clement Bidard 

François-Clément Bidard, MD PhD, is Professor of Medicine in the Department of Medical Oncology at Institut Curie & UVSQ/Université Paris-Saclay. He is also the co-coordinator of breast cancer research at Institut Curie.

Mark Gilbert, MD. 

Dr. Gilbert is a senior investigator and chief of the NIH Neuro-Oncology Branch (NOB) within NCI’s Center for Cancer Research (CCR).  

Scott Kaufmann, MD, PhD.

Dr. Kauffman is an oncologist at Mayo Clinic who also conducts research to study what happens when cancer cells are treated with targeted anti-cancer agents.

Yves Pommier, MD.

Dr. Pommier is Chief of the Developmental Therapeutics Branch at the Center for Cancer Research at the NCI and a leader on DNA topoisomerase biology and biochemistry, and their cancer relevance.

Anish Thomas, MBBS, MD

. Dr. Thomas is LASKER CLINICAL RESEARCH SCHOLAR at the Developmental Therapeutics Branch at the Center for Cancer Research at the NCI.  He is is a clinical researcher with a focus on small cell lung cancer.

Timothy Yap, MD, PhD.

Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. His main interests include the targeting of the DNA damage response (DDR) with novel therapeutics, as well as the development of novel immunotherapeutics.

Click here for more information: Management and Board of Directors